Embecta Corp. EMBC

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

Embecta Corp. (also referred to herein as "Embecta") is a leading global medical device company, primarily focused on providing solutions to improve the health and well-being of people living with diabetes. All references in this Form 10-K to "Embecta", "the Company", "we", "our" or "us" refer to Embecta Corp., a Delaware corporation, and its subsidiaries, unless otherwise indicated by the context.

Building on our 100-year centennial, we believe that our products have become one of the most widely recognized and respected brands in diabetes management throughout the world. We estimate that our products are used by more than 30 million people in over 100 countries for insulin administration and to aid with the daily management of diabetes.

Last close 6.71 2026-10-23
Market cap $380.2M 2026-06-30 share count
52-week range 2.77 - 14.91

Valuation FY2025 figures against the last close

P/S0.4x
P/E4.1x
P/FCF2.1x
EV/EBITDA5.5x
Dividend yield9.2%
Diluted EPS1.62

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue $1.08B$1.12B$1.12B$1.13B$1.17B$1.09B—
Cost of revenue $403.6M$387.9M$370.9M$354.6M$364.9M$322.9M—
Gross profit $676.8M$735.2M$749.9M$774.9M$800.4M$762.6M—
R&D $37.3M$78.8M$85.2M$66.9M$63.3M$61.4M—
SG&A $332.0M$365.1M$341.3M$294.8M$240.3M$214.7M—
Total operating expenses $434.7M$568.4M$528.4M$465.3M$308.4M$276.1M—
Operating income $242.1M$166.8M$221.5M$309.6M$492.0M$486.5M—
Pre-tax income $136.3M$44.2M$105.7M$256.6M$494.9M$485.8M—
Income tax $40.9M$34.1M$35.3M$33.0M$80.1M$58.2M—
Net income $95.4M$78.3M$70.4M$223.6M$414.8M$427.6M—
EPS, basic 1.641.361.233.927.287.50—
EPS, diluted 1.621.341.223.897.287.50—
Shares, diluted (wtd. avg.) 58.9M58.3M57.8M57.5M57.0M57.0M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents $225.5M$267.5M$326.5M$330.9M$0$0$0
Receivables $145.6M$193.0M$16.7M$22.2M$150.6M——
Inventory $178.6M$171.5M$152.1M$122.8M$118.0M——
Total current assets $631.4M$761.0M$749.1M$664.7M$291.8M——
Goodwill $15.4M$15.6M$15.6M$15.7M$15.6M——
Other intangibles $7.0M$8.1M$9.1M$8.9M$18.3M——
Total assets $1.09B$1.29B$1.21B$1.09B$788.0M——
Short-term debt $9.5M$9.5M$9.5M$9.5M$0——
Total current liabilities $261.5M$374.0M$353.5M$301.0M$164.0M——
Long-term debt $1.39B$1.57B$1.59B$1.60B$0——
Retained earnings -$445.6M-$498.6M-$541.1M-$577.1M———
Total equity -$650.6M-$738.3M-$821.7M-$891.4M$594.3M$572.2M$577.1M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating cash flow $191.7M$35.7M$67.7M$412.2M$456.3M$498.5M—
Depreciation and amortisation $40.7M$36.2M$32.6M$31.7M$38.3M$38.3M—
Stock-based compensation $31.6M$26.3M$21.5M$18.7M$12.8M$12.7M—
Capital expenditure $9.3M$15.8M$26.5M$23.6M$36.8M$41.9M—
Investing cash flow -$9.3M-$15.8M-$26.5M-$24.0M-$39.2M-$41.9M—
Financing cash flow -$226.7M-$73.4M-$48.7M-$48.0M-$417.1M-$456.6M—
Dividends paid $35.0M$34.5M$34.4M$8.6M$0$0—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001872789-25-000036.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 500M 1B 1.5B Revenue, FY2020: 1.1B Gross profit, FY2020: 762.6M Net income, FY2020: 427.6M Revenue, FY2021: 1.2B Gross profit, FY2021: 800.4M Net income, FY2021: 414.8M Revenue, FY2022: 1.1B Gross profit, FY2022: 774.9M Net income, FY2022: 223.6M Revenue, FY2023: 1.1B Gross profit, FY2023: 749.9M Net income, FY2023: 70.4M Revenue, FY2024: 1.1B Gross profit, FY2024: 735.2M Net income, FY2024: 78.3M Revenue, FY2025: 1.1B Gross profit, FY2025: 676.8M Net income, FY2025: 95.4M FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $1.09B $1.17B $1.13B $1.12B $1.12B $1.08B
Gross profit — $762.6M $800.4M $774.9M $749.9M $735.2M $676.8M
Net income — $427.6M $414.8M $223.6M $70.4M $78.3M $95.4M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Regulation FD disclosure Item 7.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%